Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. (Q43898732)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 August 2008

Language	Label	Description	Also known as
English	Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.	scientific article published on 22 August 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pasquale Comella

1

object named as

Pasquale Comella

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

2

object named as

Bruno Massidda

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

7

object named as

Luigi Maiorino

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

8

object named as

Sergio Palmeri

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Southern Italy Cooperative Oncology Group

11

object named as

Southern Italy Cooperative Oncology Group

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Gianfranco Filippelli

3

object named as

Gianfranco Filippelli

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

Antonio Farris

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Donato Natale

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Giuseppe Barberis

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Michele Cannone

9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Giovanni Condemi

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

135

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

217-226

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

https://scigraph.springernature.com/pub.10.1007/s00432-008-0454-7

0 references

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS00432-008-0454-7

21 January 2018

Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Tri

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Onco

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18719941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-008-0454-7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43898732&oldid=2104240492"